ExodusPoint Capital Management LP Invests $423,000 in Acelyrin, Inc. (NASDAQ:SLRN)

ExodusPoint Capital Management LP purchased a new position in Acelyrin, Inc. (NASDAQ:SLRN) in the fourth quarter, Holdings Channel.com reports. The fund purchased 134,680 shares of the company’s stock, valued at approximately $423,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Geode Capital Management LLC raised its holdings in Acelyrin by 3.5% in the 4th quarter. Geode Capital Management LLC now owns 1,709,086 shares of the company’s stock worth $5,368,000 after purchasing an additional 57,472 shares in the last quarter. State Street Corp increased its position in shares of Acelyrin by 10.0% during the third quarter. State Street Corp now owns 1,273,096 shares of the company’s stock valued at $6,276,000 after buying an additional 116,094 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in Acelyrin by 81.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 609,678 shares of the company’s stock worth $3,006,000 after buying an additional 273,604 shares during the period. Wellington Management Group LLP bought a new stake in Acelyrin during the 4th quarter valued at approximately $567,000. Finally, Franklin Resources Inc. grew its holdings in shares of Acelyrin by 36.9% during the 3rd quarter. Franklin Resources Inc. now owns 128,591 shares of the company’s stock worth $634,000 after acquiring an additional 34,642 shares during the period. Hedge funds and other institutional investors own 87.31% of the company’s stock.

Insider Buying and Selling

In related news, CEO Mina Kim sold 17,986 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $2.74, for a total value of $49,281.64. Following the transaction, the chief executive officer now directly owns 671,753 shares of the company’s stock, valued at approximately $1,840,603.22. This represents a 2.61 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 13.60% of the stock is currently owned by company insiders.

Acelyrin Stock Up 3.7 %

Shares of SLRN opened at $2.23 on Friday. Acelyrin, Inc. has a 52 week low of $1.85 and a 52 week high of $7.25. The stock has a market cap of $225.02 million, a P/E ratio of -0.91 and a beta of 1.12. The business’s 50 day moving average price is $2.43 and its 200-day moving average price is $3.54.

Acelyrin (NASDAQ:SLRN) last released its earnings results on Wednesday, March 19th. The company reported ($0.79) EPS for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.07. On average, equities analysts anticipate that Acelyrin, Inc. will post -2.53 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Citigroup lowered their target price on Acelyrin from $6.00 to $3.00 and set a “neutral” rating for the company in a research note on Tuesday, January 7th. HC Wainwright dropped their target price on shares of Acelyrin from $8.00 to $6.00 and set a “neutral” rating on the stock in a report on Tuesday, January 7th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, Acelyrin presently has a consensus rating of “Hold” and a consensus target price of $9.60.

Acelyrin Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.